No Record Found
No Record Found
Sector
PharmaceuticalsOpen
₹27.5Prev. Close
₹27.74Turnover(Lac.)
₹14.05Day's High
₹30Day's Low
₹27.552 Week's High
₹7052 Week's Low
₹27.1Book Value
₹16.38Face Value
₹10Mkt Cap (₹ Cr.)
100.41P/E
0EPS
0Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 35.27 | 35.27 | 21.44 | 10.27 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 28.52 | 35.79 | 0.98 | -1.6 |
Net Worth | 63.79 | 71.06 | 22.42 | 8.67 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 3.93 | 8.55 | 0 | 0.44 |
yoy growth (%) | -53.93 | 0 | -100 | -62.64 |
Raw materials | -3.57 | -8.15 | 0 | -0.49 |
As % of sales | 90.66 | 95.41 | 0 | 110.08 |
Employee costs | -0.04 | -0.04 | -0.02 | -0.06 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 0.14 | 0.08 | -0.37 | -0.36 |
Depreciation | 0 | -0.04 | -0.03 | 0 |
Tax paid | 0 | 0 | 0.4 | -0.01 |
Working capital | -0.05 | -0.09 | -0.16 | -0.62 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -53.93 | 0 | -100 | -62.64 |
Op profit growth | 28.21 | -131.86 | -13.1 | 12.42 |
EBIT growth | 61.7 | -123.62 | 1.95 | -7.53 |
Net profit growth | 55.54 | 178.26 | -108.69 | -451.66 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 |
|---|---|---|---|
Gross Sales | 19.45 | 15.11 | 0 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 19.45 | 15.11 | 0 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 0.1 | 0.88 | 0 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,840.55 | 147.13 | 4,41,609.6 | 608.7 | 0.87 | 4,887.27 | 93.23 |
Divis Laboratories Ltd DIVISLAB | 6,753.3 | 67.34 | 1,79,278.9 | 756 | 0.44 | 2,793 | 629.49 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,451.2 | 67.12 | 1,50,648.83 | 467 | 0 | 2,677 | 249.73 |
Cipla Ltd CIPLA | 1,417.05 | 30.93 | 1,14,469.38 | 384.64 | 0.92 | 3,840.92 | 423.38 |
Dr Reddys Laboratories Ltd DRREDDY | 1,329.35 | 34.46 | 1,10,955.12 | -219.4 | 0.6 | 3,802.6 | 375.78 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman(Non Exe)&Dir(Non-Ind)
Shankarappa Nagaraja Vinaya Babu
Independent Non Exe. Director
P N Vijay
Independent Non Exe. Director
M Sudheer Anand
Independent Non Exe. Director
Methuku Nagesh
Non-Exec & Non-Independent Dir
Shreedhara Shetty
Non Executive Director / Chief Financial Officer
Balagangadhara Bc
Company Sec. & Compli. Officer
Prasanna Subramanya Bhat
4-4-211/212/3 1st Floor,
Inderbagh Sulthan Bazar,
Telangana - 500095
Tel: 91-40-66669809
Website: http://www.pharmaids.com
Email: compliance@pharmaids.com
12-10-167,
Bharath Nagar,
Hyderbad - 500018
Tel: 91-040-23818475/76/2
Website: www.vccilindia.com
Email: info@vccilindia.com
Summary
Pharmaids Pharmaceuticals Limited, incorporated in March, 1989 at Hyderabad, Telangana were suppliers of Quality Grade range of speciality chemicals, skin care, hospital care and generic products in t...
Read More
Reports by Pharmaids Pharmaceuticals Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.